Arbutus Biopharma (ABUS) to Post Quarterly Earnings on Wednesday

Arbutus Biopharma (NASDAQ:ABUS) is expected to be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Arbutus Biopharma to post earnings of ($0.02) per share and revenue of $0.70 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Arbutus Biopharma (NASDAQ:ABUS) last released its earnings results on Tuesday, March 31st. The biopharmaceutical company reported $0.87 EPS for the quarter. The company had revenue of $179.13 million during the quarter. Arbutus Biopharma had a net margin of 83.95% and a return on equity of 129.32%.

Arbutus Biopharma Price Performance

Shares of NASDAQ:ABUS opened at $4.41 on Wednesday. Arbutus Biopharma has a fifty-two week low of $3.26 and a fifty-two week high of $5.38. The firm’s 50-day simple moving average is $4.54 and its 200-day simple moving average is $4.41. The company has a market cap of $871.15 million, a price-to-earnings ratio of 5.31 and a beta of 0.62.

Institutional Trading of Arbutus Biopharma

A number of institutional investors have recently bought and sold shares of ABUS. Morgan Stanley increased its position in shares of Arbutus Biopharma by 9.2% in the fourth quarter. Morgan Stanley now owns 26,702,776 shares of the biopharmaceutical company’s stock valued at $128,440,000 after buying an additional 2,252,164 shares in the last quarter. Two Seas Capital LP grew its stake in Arbutus Biopharma by 5.2% in the 3rd quarter. Two Seas Capital LP now owns 10,991,261 shares of the biopharmaceutical company’s stock valued at $49,900,000 after acquiring an additional 547,944 shares during the last quarter. State Street Corp grew its stake in Arbutus Biopharma by 44.2% in the 4th quarter. State Street Corp now owns 5,908,211 shares of the biopharmaceutical company’s stock valued at $28,418,000 after acquiring an additional 1,809,893 shares during the last quarter. ADAR1 Capital Management LLC increased its holdings in Arbutus Biopharma by 86.5% during the 4th quarter. ADAR1 Capital Management LLC now owns 5,415,109 shares of the biopharmaceutical company’s stock valued at $26,047,000 after acquiring an additional 2,511,883 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Arbutus Biopharma by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 3,677,307 shares of the biopharmaceutical company’s stock worth $17,691,000 after acquiring an additional 11,145 shares during the last quarter. 43.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on ABUS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arbutus Biopharma in a research report on Friday, July 17th. Wall Street Zen raised Arbutus Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Arbutus Biopharma presently has a consensus rating of “Hold” and a consensus target price of $5.00.

About Arbutus Biopharma

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.